CARsgen Therapeutics Holdings Limited, a company specializing in innovative CAR T-cell therapies for hematologic malignancies and solid tumors, recently announced the initial results from the ongoing first-in-human study of CT071 at the 29th Annual Congress of the European Hematology Association (EHA) held in Shanghai on June 15, 2024.
The Phase I study of CT071, presented at the congress, focused on GPRC5D-targeted CAR T cells and their potential in treating relapsed or refractory multiple myeloma. Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics, highlighted the need for novel therapies in addressing the challenges of multiple myeloma, emphasizing the promising role of GPRC5D as a therapeutic target.
As of February 28, 2024, ten patients had received CT071, with encouraging results. The treatment demonstrated a 90% overall response rate, including stringent complete responses in 50% of patients. Importantly, all patients with evaluable minimal residual disease assessments achieved negativity, showcasing the potential efficacy of CT071 in treating multiple myeloma.
The safety profile of CT071 was also notable, with no Grade 3 or higher cytokine release syndrome events reported. Moreover, there were no instances of immune effector cell-associated neurotoxicity syndrome observed, underscoring the favorable safety profile of the therapy.
CT071 is a CAR T-cell therapy developed using CARsgen’s proprietary CARcelerate platform to target GPRC5D for the treatment of relapsed or refractory multiple myeloma and plasma cell leukemia. Ongoing clinical trials in China are evaluating the safety and efficacy of CT071 in various patient populations, further advancing the understanding of its potential as a treatment option.
CARsgen Therapeutics, with operations in China and the U.S., is dedicated to developing innovative CAR T-cell therapies for a range of cancers. The company’s comprehensive research and development platform aims to address key challenges in CAR T-cell therapy, such as improving safety and efficacy in treating solid tumors, with the ultimate goal of making cancer a curable disease.
The presentation of CT071’s initial results at EHA 2024 marks a significant milestone in the advancement of CAR T-cell therapy for multiple myeloma, offering new hope for patients with this challenging disease. As research continues and more data becomes available, the potential of CT071 to become a leading CAR T-cell therapy in the field remains promising.
